Clinical trials: Triple-Negative Breast Carcinoma
Advanced Solid Tumors
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors.
- Trial name
- NCT02460224
- Testing
- LAG525, PDR001
- Where
- 24 sites in United States, Australia and 10 more
- Volunteers
- 490 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Triple Negative Breast Cancer
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
This is a phase 1b/2 open-label study to evaluate the safety and efficacy of sacituzumab govitecan-hziy in combination with chemoimmunotherapy (cyclophosphamide, N-803, and PD-L1 t-haNK) in subjects with Triple Negative Breast…
- Trial name
- NCT04927884
- Testing
- N-803, PD-L1 t-haNK, Sacituzumab Govitecan-Hziy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- ImmunityBio, Inc.
Triple-Negative Breast Neoplasms, Breast Neoplasm
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
This was a study to investigate the potential clinical benefit of trilaciclib (G1T28) in preserving the bone marrow and the immune system, and enhancing chemotherapy antitumor efficacy when administered prior to carboplatin and…
- Conditions
- Triple-Negative Breast Neoplasms, Breast Neoplasm, Breast Cancer, Triple-Negative Breast Cancer
- Trial name
- NCT02978716
- Testing
- Trilaciclib, Gemcitabine, Carboplatin
- Where
- 54 sites in United States, Belgium and 6 more
- Volunteers
- 102 people
- Sponsor
- G1 Therapeutics, Inc.
Locally Advanced or Metastatic Solid Tumors
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2…
- Trial name
- NCT03150810
- Testing
- Pamiparib, Temozolomide
- Where
- 22 sites in United States, Australia and 2 more
- Volunteers
- 139 people
- Sponsor
- BeiGene
Metastatic Breast Cancer, Recurrent Ovarian Carcinoma
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination.
- Trial name
- CHARGE (NCT04315233)
- Testing
- Ribociclib, Belinostat
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Utah
Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
This randomized phase II trial studies how well docosahexaenoic acid works in preventing recurrence in breast cancer survivors. Docosahexaenoic acid supplement may prevent recurrence in breast cancer survivors.
- Conditions
- Benign Breast Neoplasm, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Lobular Breast Carcinoma In Situ
- Trial name
- NCT01849250
- Testing
- Docosahexaenoic Acid
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Triple-negative Breast Cancer
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
The main purpose of this study was to assess the antitumor activity of three combinations: i) LAG525 + spartalizumab; ii) LAG525 + spartalizumab + carboplatin, and iii) LAG525 + carboplatin in participants with advanced…
- Trial name
- NCT03499899
- Testing
- LAG525, PDR001, Carboplatin
- Where
- 33 sites in United States, Argentina and 15 more
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Brain Metastases, Breast Cancer
STAR Cape+BKM120 MBC With Brain Met
This is a study to determine the safety and effectiveness of BKM120 plus capecitabine in breast cancer patients with brain metastases. Both capecitabine and BMK120 have previously shown activity in patients with breast cancer.
- Conditions
- Brain Metastases, Breast Cancer, Metastatic Breast Cancer
- Trial name
- NCT02000882
- Testing
- BKM120, capecitabine, Trastuzumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- US Oncology Research
Triple Negative Breast Neoplasms
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
The main purpose of this study was to evaluate bintrafusp alfa monotherapy in participants with triple negative breast cancer (TNBC) who express high levels of HMGA2 as determined by a centralized reverse transcriptase-polymerase…
- Trial name
- NCT04489940
- Testing
- Bintrafusp alfa
- Where
- 45 sites in United States, Belgium and 4 more
- Volunteers
- 11 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Metastatic Breast Cancer
Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer
It is a phase II trial to explore the efficacy and safety of cisplatin plus capecitabine in anthracycline and taxane-pretreated metastatic triple negative breast cancer patients.
- Trial name
- NCT01928680
- Testing
- Cisplatin/Capecitabine
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Chinese Academy of Medical Sciences
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
This phase I trial studies how well chemokine modulation therapy and standard chemotherapy given before surgery work in treating patients with early stage triple negative breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT04081389
- Testing
- Celecoxib, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Female Breast Cancer
Estrogen for Triple Negative Breast Cancer
The purpose of this study is to determine the effectiveness of Estradiol treatment for advanced breast cancer that is hormone receptor negative and Her2/neu negative.
- Trial name
- NCT01083641
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Wisconsin, Madison
Brain Metastases, Adult
Neoadjuvant Immunotherapy in Brain Metastases
The purpose of this phase 2 study is to assess the feasibility and efficacy of neoadjuvant immunotherapy in patients with previously untreated, surgically-resectable, solid tumor brain metastases.
- Trial name
- NCT04434560
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sarah Sammons, MD
Estrogen Receptor Negative, Estrogen Receptor Positive
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer
This partially randomized phase Ib/II trial studies the side effects and best dose of taselisib when given together with enzalutamide and to see how well they work in treating patients with androgen receptor positive…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT02457910
- Testing
- Biomarker Analysis, Enzalutamide, Pharmacological Study
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Triple-Negative Breast Cancer
Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer
The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of magrolimab in combination with nab-paclitaxel or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in…
- Trial name
- ELEVATE TNBC (NCT04958785)
- Testing
- Magrolimab, Nab-Paclitaxel, Paclitaxel
- Where
- 45 sites in United States, Australia and 4 more
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
Advanced Breast Cancer, HER2/Neu Negative
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or tumor genomic alterations.
- Conditions
- Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer
- Trial name
- NCT02401347
- Testing
- Talazoparib Tosylate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Melinda Telli
Breast Cancer
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
RATIONALE: Neoadjuvant chemotherapy for women with stage II-III Her negative breast cancer followed by Her2Bi armed activated T cells (ATCs) may significantly improve the pathologic complete response (pCR) rate at the time of…
- Trial name
- NCT01147016
- Testing
- HER2Bi-armed activated T cells, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Advanced Cancer, Advanced Solid Tumor
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
This study is an open-label, multi-arm, parallel cohort, dose validation and expansion design. The study is modular in design, allowing evaluation of the safety, efficacy and pharmacokinetics (PK) of NUC-3373 in combination with…
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant, Metastatic Cancer
- Trial name
- NCT05714553
- Testing
- Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab
- Where
- 4 sites in United Kingdom
- Volunteers
- 19 people
- Sponsor
- NuCana plc
Estrogen Receptor Negative, Estrogen Receptor Positive
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
This phase II trial studies the side effects and how well giving paclitaxel and cyclophosphamide with or without trastuzumab before surgery works in treating patients with previously untreated breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT01750073
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis
- Where
- 4 sites in United States
- Volunteers
- 92 people
- Sponsor
- University of Nebraska
Neoplasms, Breast Cancer
A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors
To assess the safety and tolerability at increasing dose levels of PF-06650808 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT02129205
- Testing
- PF-06650808
- Where
- 11 sites in United States
- Volunteers
- 40 people
- Sponsor
- Pfizer